1/12
08:00 am
elut
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Medium
Report
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
1/9
08:13 am
elut
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery [Yahoo! Finance]
Medium
Report
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery [Yahoo! Finance]
1/9
08:00 am
elut
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
Medium
Report
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
11/8
01:12 am
elut
Low
Report
11/6
04:05 pm
elut
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development
Medium
Report
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development
10/24
12:21 pm
elut
Elutia (NASDAQ:ELUT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Elutia (NASDAQ:ELUT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/23
04:05 pm
elut
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Low
Report
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025